tolterodine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2705 124937-51-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tolterodine
  • tolterodine tartrate
  • (+)-Tolterodine
  • (R)-Tolterodine
An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE.
  • Molecular weight: 325.50
  • Formula: C22H31NO
  • CLOGP: 5.24
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 23.47
  • ALOGS: -4.78
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 12 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 1 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 24.58 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution) 1.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 8.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.04 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
March 25, 1998 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 112.04 11.79 280 22737 240233 56028817
Sensitivity to weather change 98.36 11.79 50 22967 6599 56262451
Urinary incontinence 96.87 11.79 87 22930 29498 56239552
Multiple sclerosis 83.69 11.79 78 22939 27724 56241326
Multiple sclerosis relapse 82.95 11.79 97 22920 44806 56224244
Dry mouth 79.82 11.79 114 22903 64091 56204959
Fall 72.87 11.79 314 22703 357196 55911854
Pollakiuria 72.58 11.79 69 22948 25133 56243917
Hypertonic bladder 65.01 11.79 30 22987 3202 56265848
Maternal exposure during pregnancy 58.92 11.79 5 23012 189548 56079502
Contraindicated product administered 55.03 11.79 6 23011 186280 56082770
Bladder disorder 53.54 11.79 36 22981 7988 56261062
Nocturia 47.70 11.79 32 22985 7074 56261976
Antinuclear antibody negative 47.03 11.79 12 23005 204 56268846
Treatment failure 46.67 11.79 7 23010 170385 56098665
Coombs positive haemolytic anaemia 45.99 11.79 13 23004 331 56268719
Off label use 40.82 11.79 106 22911 556074 55712976
Glossodynia 37.98 11.79 8 23009 152450 56116600
Drug intolerance 37.40 11.79 32 22985 264786 56004264
Herpes simplex reactivation 37.08 11.79 12 23005 488 56268562
Cerebrovascular accident 35.48 11.79 105 22912 99165 56169885
Infusion related reaction 35.05 11.79 21 22996 208910 56060140
Systemic lupus erythematosus 34.84 11.79 15 23002 180063 56088987
Exposure during pregnancy 34.28 11.79 7 23010 136335 56132715
Hallucination, auditory 34.03 11.79 32 22985 11492 56257558
Paranoia 33.98 11.79 31 22986 10713 56258337
Stress urinary incontinence 31.25 11.79 16 23001 2142 56266908
Wound 31.23 11.79 9 23008 138795 56130255
Micturition urgency 31.08 11.79 27 22990 8754 56260296
Rheumatoid arthritis 30.31 11.79 70 22947 382534 55886516
Bladder spasm 29.89 11.79 14 23003 1545 56267505
Depression 29.77 11.79 149 22868 179968 56089082
Urinary retention 29.36 11.79 46 22971 28028 56241022
Balance disorder 29.32 11.79 83 22934 76437 56192613
Gastritis haemorrhagic 28.01 11.79 13 23004 1406 56267644
Dizziness 27.96 11.79 255 22762 375885 55893165
Transient ischaemic attack 27.10 11.79 49 22968 33528 56235522
Hyperlipidaemia 26.79 11.79 35 22982 18074 56250976
Antiphospholipid syndrome 26.36 11.79 13 23004 1608 56267442
Coronary artery disease 26.21 11.79 46 22971 30750 56238300
Abdominal discomfort 25.98 11.79 46 22971 277228 55991822
Gastrooesophageal reflux disease 25.97 11.79 84 22933 83173 56185877
Complex regional pain syndrome 23.06 11.79 13 23004 2110 56266940
Oesophagitis 22.09 11.79 28 22989 14029 56255021
Swelling 21.37 11.79 41 22976 239730 56029320
Pericarditis 21.17 11.79 9 23008 108914 56160136
Incontinence 21.17 11.79 24 22993 10711 56258339
Hepatic enzyme increased 20.41 11.79 24 22993 171360 56097690
Gait disturbance 20.22 11.79 125 22892 163196 56105854
Mental status changes 19.89 11.79 46 22971 37455 56231595
Hypothyroidism 19.33 11.79 46 22971 38150 56230900
Infection 18.93 11.79 33 22984 200173 56068877
Anxiety disorder 18.27 11.79 14 23003 3806 56265244
Pain 18.01 11.79 179 22838 663005 55606045
Myocardial infarction 17.62 11.79 80 22937 92790 56176260
Urge incontinence 17.45 11.79 8 23009 841 56268209
Product use issue 17.29 11.79 31 22986 186010 56083040
White blood cell count abnormal 16.76 11.79 16 23001 5851 56263199
Iliac artery occlusion 16.66 11.79 5 23012 158 56268892
Constipation 16.56 11.79 140 22877 201803 56067247
Stomatitis 16.55 11.79 15 23002 120795 56148255
Barrett's oesophagus 16.54 11.79 7 23010 608 56268442
Secondary progressive multiple sclerosis 16.52 11.79 9 23008 1366 56267684
Osteonecrosis 16.39 11.79 32 22985 23183 56245867
Liver iron concentration abnormal 16.27 11.79 4 23013 58 56268992
Toxicity to various agents 16.25 11.79 43 22974 224521 56044529
Peritonitis 16.18 11.79 26 22991 16176 56252874
Drug abuse 15.92 11.79 4 23013 67606 56201444
Dysphagia 15.85 11.79 71 22946 81876 56187174
Aphonia 15.83 11.79 19 22998 9010 56260040
Completed suicide 15.65 11.79 19 22998 133814 56135236
Neutrophil count abnormal 15.51 11.79 11 23006 2659 56266391
Cardiac failure congestive 15.49 11.79 74 22943 87646 56181404
Body temperature fluctuation 15.45 11.79 10 23007 2082 56266968
Drug hypersensitivity 15.34 11.79 176 22841 275029 55994021
Mixed incontinence 14.97 11.79 4 23013 82 56268968
Confusional state 14.85 11.79 140 22877 208015 56061035
Product complaint 14.77 11.79 21 22996 11739 56257311
Malignant neoplasm progression 14.43 11.79 6 23011 73581 56195469
Varicose ulceration 14.34 11.79 6 23011 506 56268544
Neurogenic bladder 14.26 11.79 11 23006 3018 56266032
Colitis ischaemic 14.25 11.79 19 22998 10001 56259049
Haemoglobin abnormal 14.01 11.79 13 23004 4591 56264459
Discomfort 13.73 11.79 23 22994 141738 56127312
Arthropathy 13.27 11.79 40 22977 200235 56068815
Neutropenia 13.26 11.79 28 22989 158139 56110911
Blister 13.22 11.79 15 23002 108872 56160178
Increased appetite 13.10 11.79 17 23000 8718 56260332
Perforation 13.00 11.79 7 23010 1039 56268011
Escherichia urinary tract infection 12.91 11.79 19 22998 10956 56258094
Chronic obstructive pulmonary disease 12.85 11.79 52 22965 57363 56211687
Irritable bowel syndrome 12.76 11.79 6 23011 68452 56200598
Visual impairment 12.67 11.79 62 22955 74140 56194910
Psychotic disorder 12.60 11.79 29 22988 23529 56245521
Skin disorder 12.58 11.79 31 22986 26278 56242772
Pathological fracture 12.53 11.79 16 23001 8073 56260977
Therapy non-responder 12.50 11.79 54 22963 61301 56207749
Febrile neutropenia 12.32 11.79 15 23002 105530 56163520
Cystitis 12.26 11.79 46 22971 48992 56220058
Haemoglobin 12.12 11.79 4 23013 173 56268877
Blood triglycerides increased 12.02 11.79 19 22998 11658 56257392

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seronegative arthritis 66.08 15.20 19 7080 957 31689288
Lipoma 57.50 15.20 19 7080 1524 31688721
Pollakiuria 51.55 15.20 38 7061 17864 31672381
Dry mouth 51.18 15.20 43 7056 24415 31665830
Fall 46.90 15.20 118 6981 185971 31504274
Urinary incontinence 45.94 15.20 35 7064 17285 31672960
Prostatic specific antigen increased 41.84 15.20 30 7069 13508 31676737
Urinary retention 39.43 15.20 43 7056 33682 31656563
Inflammatory marker increased 39.17 15.20 19 7080 4159 31686086
Balance disorder 39.11 15.20 45 7054 37377 31652868
Musculoskeletal discomfort 32.45 15.20 20 7079 7003 31683242
Micturition urgency 30.75 15.20 18 7081 5742 31684503
Multiple sclerosis 29.98 15.20 20 7079 8017 31682228
Urinary tract infection 22.78 15.20 52 7047 76817 31613428
Confusional state 21.35 15.20 72 7027 133262 31556983
Failure to thrive 20.90 15.20 16 7083 7946 31682299
Bladder disorder 20.77 15.20 11 7088 2891 31687354
Asthenia 20.56 15.20 102 6997 224653 31465592
Cerebrovascular accident 20.56 15.20 51 7048 79433 31610812
Nocturia 18.82 15.20 16 7083 9219 31681026
Faecaloma 18.37 15.20 12 7087 4644 31685601
Gait inability 18.29 15.20 22 7077 19122 31671123
Multiple sclerosis relapse 17.00 15.20 17 7082 12030 31678215
Incontinence 16.78 15.20 12 7087 5374 31684871
Hypertonic bladder 16.61 15.20 8 7091 1722 31688523
Dizziness 16.54 15.20 88 7011 199059 31491186
Blood pressure systolic increased 16.39 15.20 21 7078 19449 31670796
Rectal tenesmus 15.44 15.20 6 7093 768 31689477
Toxicity to various agents 15.33 15.20 11 7088 181476 31508769

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis 101.59 11.96 76 22905 25209 70880254
Urinary tract infection 100.84 11.96 238 22743 248531 70656932
Urinary incontinence 90.02 11.96 84 22897 37758 70867705
Sensitivity to weather change 89.36 11.96 45 22936 7360 70898103
Fall 81.15 11.96 321 22660 443775 70461688
Multiple sclerosis relapse 73.83 11.96 80 22901 42937 70862526
Pollakiuria 64.12 11.96 66 22915 33395 70872068
Bladder disorder 57.57 11.96 35 22946 8254 70897209
Dry mouth 53.66 11.96 88 22893 70369 70835094
Cerebrovascular accident 50.33 11.96 130 22851 143340 70762123
Lipoma 49.05 11.96 22 22959 2780 70902683
Hypertonic bladder 48.63 11.96 24 22957 3759 70901704
Balance disorder 42.86 11.96 92 22889 90036 70815427
Off label use 40.39 11.96 116 22865 742944 70162519
Micturition urgency 36.75 11.96 30 22951 11284 70894179
Seronegative arthritis 36.33 11.96 19 22962 3360 70902103
Urinary retention 35.22 11.96 62 22919 52458 70853005
Dizziness 33.55 11.96 261 22720 463880 70441583
Drug abuse 31.47 11.96 5 22976 147251 70758212
Prostatic specific antigen increased 30.53 11.96 25 22956 9441 70896022
Toxicity to various agents 30.46 11.96 48 22933 382124 70523339
Incontinence 29.21 11.96 28 22953 13000 70892463
Hallucination, auditory 26.18 11.96 31 22950 18297 70887166
Bladder spasm 25.96 11.96 13 22968 2100 70903363
Contraindicated product administered 25.74 11.96 6 22975 134606 70770857
Stress urinary incontinence 25.67 11.96 12 22969 1668 70903795
Maternal exposure during pregnancy 24.46 11.96 4 22977 115341 70790122
Musculoskeletal discomfort 23.58 11.96 29 22952 17803 70887660
Nocturia 23.24 11.96 24 22957 12180 70893283
Treatment failure 22.91 11.96 9 22972 144133 70761330
Febrile neutropenia 22.31 11.96 20 22961 204298 70701165
Secondary progressive multiple sclerosis 21.62 11.96 10 22971 1357 70904106
Confusional state 21.09 11.96 161 22820 284237 70621226
Paranoia 21.08 11.96 27 22954 17261 70888202
Inflammatory marker increased 20.92 11.96 20 22961 9254 70896209
Asthenia 20.74 11.96 233 22748 457433 70448030
Systemic lupus erythematosus 20.59 11.96 4 22977 101898 70803565
Gait inability 18.90 11.96 45 22936 47130 70858333
Transient ischaemic attack 18.59 11.96 44 22937 45900 70859563
Hand deformity 18.33 11.96 3 22978 86479 70818984
Drug intolerance 18.29 11.96 28 22953 225659 70679804
Drug hypersensitivity 18.03 11.96 146 22835 262313 70643150
Gastrooesophageal reflux disease 17.58 11.96 67 22914 90772 70814691
Vision blurred 17.52 11.96 69 22912 94915 70810548
Infusion related reaction 17.50 11.96 23 22958 197511 70707952
Aphonia 17.27 11.96 18 22963 9233 70896230
Body temperature fluctuation 17.27 11.96 12 22969 3547 70901916
Liver iron concentration abnormal 17.20 11.96 4 22977 58 70905405
Mental status changes 17.01 11.96 52 22929 63049 70842414
Exposure during pregnancy 16.59 11.96 4 22977 87713 70817750
Coronary artery disease 16.26 11.96 51 22930 62685 70842778
Speech disorder 14.88 11.96 43 22938 50537 70854926
Iliac artery occlusion 14.82 11.96 5 22976 294 70905169
Product complaint 14.75 11.96 19 22962 12212 70893251
Urge incontinence 14.42 11.96 7 22974 1058 70904405
Depression 14.38 11.96 112 22869 198862 70706601
Blood pressure systolic increased 14.34 11.96 46 22935 57213 70848250
Escherichia urinary tract infection 14.30 11.96 19 22962 12588 70892875
Colitis ischaemic 14.06 11.96 20 22961 14117 70891346
Neutropenia 14.01 11.96 40 22941 257116 70648347
Neutrophil count decreased 13.64 11.96 5 22976 83551 70821912
Stomatitis 13.52 11.96 13 22968 128498 70776965
Bladder adenocarcinoma stage unspecified 13.50 11.96 3 22978 35 70905428
Orthostatic hypotension 13.35 11.96 42 22939 51701 70853762
Perforation 13.28 11.96 7 22974 1258 70904205
Barrett's oesophagus 13.22 11.96 6 22975 779 70904684
Psychotic disorder 13.03 11.96 34 22947 37667 70867796
Cystitis 12.95 11.96 39 22942 46902 70858561
Wound 12.91 11.96 8 22973 98724 70806739
Dysphagia 12.71 11.96 71 22910 112763 70792700
Mixed incontinence 12.68 11.96 3 22978 47 70905416
Completed suicide 12.61 11.96 35 22946 227100 70678363
Multiple organ dysfunction syndrome 12.60 11.96 10 22971 108505 70796958
Body height decreased 12.52 11.96 14 22967 7769 70897694
Dysarthria 12.08 11.96 46 22935 62267 70843196
Hyperlipidaemia 12.08 11.96 25 22956 23838 70881625
Increased appetite 12.04 11.96 16 22965 10597 70894866
Malignant neoplasm progression 12.03 11.96 13 22968 121726 70783737
Palpitations 12.02 11.96 69 22912 110684 70794779
Urosepsis 12.02 11.96 25 22956 23924 70881539

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G04BD07 GENITO URINARY SYSTEM AND SEX HORMONES
UROLOGICALS
UROLOGICALS
Drugs for urinary frequency and incontinence
FDA MoA N0000000125 Cholinergic Muscarinic Antagonists
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D064804 Urological Agents
CHEBI has role CHEBI:48876 muscarinic antagonists
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:53784 antispasmodics
FDA EPC N0000175700 Cholinergic Muscarinic Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Urgent desire to urinate indication 75088002
Urge incontinence of urine indication 87557004
Bladder muscle dysfunction - overactive indication 236633002
Increased Urinary Frequency indication
Torsades de pointes contraindication 31722008
Dementia contraindication 52448006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Myasthenia gravis contraindication 91637004 DOID:437
Prolonged QT interval contraindication 111975006
Bladder outflow obstruction contraindication 236645006
Pyloric obstruction contraindication 244815007
Retention of urine contraindication 267064002
Gastric retention contraindication 307227006
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastrointestinal hypomotility contraindication 421807004
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Congenital long QT syndrome contraindication 442917000
Aggravated Glaucoma contraindication




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.83 acidic
pKa2 9.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 8.49 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 8.57 CHEMBL CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 8.51 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR Ki 8.66 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 7.77 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8.85 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 8.16 CHEMBL
Muscarinic acetylcholine receptor M1 GPCR Ki 8.85 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 8.15 CHEMBL
Muscarinic acetylcholine receptor M5 GPCR Ki 8.66 CHEMBL
Muscarinic acetylcholine receptor M4 GPCR Ki 8.51 CHEMBL

External reference:

IDSource
4024113 VUID
N0000022118 NUI
D00646 KEGG_DRUG
124937-52-6 SECONDARY_CAS_RN
4021103 VANDF
4024113 VANDF
C0388753 UMLSCUI
CHEBI:9622 CHEBI
CHEMBL1382 ChEMBL_ID
DB01036 DRUGBANK_ID
CHEMBL1722209 ChEMBL_ID
D000068737 MESH_DESCRIPTOR_UI
443879 PUBCHEM_CID
360 IUPHAR_LIGAND_ID
6768 INN_ID
WHE7A56U7K UNII
119565 RXNORM
191519 MMSL
5600 MMSL
d04294 MMSL
007444 NDDF
007445 NDDF
109113000 SNOMEDCT_US
372570008 SNOMEDCT_US
386971005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Detrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-4541 TABLET, FILM COATED 1 mg ORAL NDA 25 sections
Detrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-4544 TABLET, FILM COATED 2 mg ORAL NDA 25 sections
Detrol LA HUMAN PRESCRIPTION DRUG LABEL 1 0009-5190 CAPSULE, EXTENDED RELEASE 2 mg ORAL NDA 29 sections
Detrol LA HUMAN PRESCRIPTION DRUG LABEL 1 0009-5191 CAPSULE, EXTENDED RELEASE 4 mg ORAL NDA 29 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0010 TABLET, FILM COATED 1 mg ORAL ANDA 25 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0010 TABLET, FILM COATED 1 mg ORAL ANDA 25 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0018 TABLET, FILM COATED 2 mg ORAL ANDA 25 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-0018 TABLET, FILM COATED 2 mg ORAL ANDA 25 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7163 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 26 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7163 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 26 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7164 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0093-7164 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6592 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 20 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 0904-6593 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 20 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-706 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 22 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-706 TABLET, EXTENDED RELEASE 1 mg ORAL ANDA 22 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-707 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 22 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 10135-707 TABLET, EXTENDED RELEASE 2 mg ORAL ANDA 22 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-189 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 21 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-189 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 21 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-189 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 21 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-190 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 21 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-190 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 21 sections
TOLTERODINE TARTRATE HUMAN PRESCRIPTION DRUG LABEL 1 13668-190 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 21 sections
Tolterodine Tartrate Human Prescription Drug Label 1 16571-126 TABLET, FILM COATED 1 mg ORAL ANDA 21 sections
Tolterodine Tartrate Human Prescription Drug Label 1 16571-127 TABLET, FILM COATED 2 mg ORAL ANDA 21 sections
DETROL HUMAN PRESCRIPTION DRUG LABEL 1 16590-959 TABLET, FILM COATED 2 mg ORAL NDA 23 sections
Tolterodine tartrate Human Prescription Drug Label 1 27241-191 CAPSULE, EXTENDED RELEASE 2 mg ORAL ANDA 26 sections
Tolterodine tartrate Human Prescription Drug Label 1 27241-192 CAPSULE, EXTENDED RELEASE 4 mg ORAL ANDA 26 sections
Tolterodine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 29300-239 TABLET 1 mg ORAL ANDA 20 sections